World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0018609845
Reproduction Date:

Title: Cjc-1295  
Author: World Heritage Encyclopedia
Language: English
Subject: Growth-hormone-releasing hormone, Peptide, ConjuChem, Sandor Earl, Peptides
Collection: Growth Hormone Secretagogues, Growth Hormone-Releasing Hormone Receptor Agonists, Hormonal Agents, Peptides
Publisher: World Heritage Encyclopedia


Clinical data
Legal status
  • Investigational
Routes Subcutaneous injection
CAS number
ATC code None
Chemical data
Formula C152H252N44O42 
Mol. mass 3367.90 g/mol

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was invented by ConjuChem, a Canadian biotechnology company.

One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.[1]


The reason why CJC-1295 possesses the ability to lengthen the half-life within the active agent has to do with the scientific process known as bioconjugation. This technology, which is relatively new, is defined by its ability to take a reactive group and bond it to a peptide. This attachment causes a reaction with a nucleophilic unit, a typically partially molecule that is found within the bloodstream of an animal test subject. This reaction in turn causes a more stable bond to occur. This specific peptide has an especially high attraction to albumin, a globular protein that is soluble in water. This affinity prohibits natural degradation, which in turn increases the peptide’s half-life. Additionally, clinical research performed on animal test subjects has thus far shown that there have been no signs of DPP-IV degradation present when CJC-1295 was introduced.[2]

See also


  1. ^ Teichman, Sam. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". JCEM. Retrieved 27 September 2013. 
  2. ^ Stand, Kim (24 September 2013). "Current Research Findings Regarding CJC-1295". EP. Retrieved 27 September 2013. 

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.